George P Kim

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
    George P Kim
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 25:767-72. 2007
  2. ncbi request reprint Treatment options for hepatobiliary and pancreatic cancer
    Steven R Alberts
    Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:628-37. 2007
  3. pmc Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
    George P Kim
    College of Medicine, Mayo Clinic
    Biologics 2:223-8. 2008
  4. pmc An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
    George P Kim
    Mayo Clinic Florida, Jacksonville, FL, USA
    Invest New Drugs 30:387-94. 2012
  5. ncbi request reprint Oxaliplatin in the treatment of colorectal cancer
    George P Kim
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32082, USA
    Expert Opin Drug Metab Toxicol 3:281-94. 2007
  6. pmc Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
    George P Kim
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:2848-54. 2009
  7. pmc Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials
    Frank A Sinicrope
    North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:406-12. 2012
  8. ncbi request reprint Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway
    George P Kim
    Division of Hematology Oncology, Mayo Clinic Jacksonville, FL, USA
    Clin Colorectal Cancer 5:S89-97. 2005
  9. pmc DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Natl Cancer Inst 103:863-75. 2011
  10. doi request reprint Retransplantation for donor-derived neuroendocrine tumor
    Rehana Begum
    Department of Transplant, Mayo Clinic, Jacksonville, FL 32224, USA
    Liver Transpl 17:83-7. 2011

Detail Information

Publications20

  1. ncbi request reprint Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
    George P Kim
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 25:767-72. 2007
    ..The role of high-degree microsatellite instability (MSI-H) as a marker to predict benefit from adjuvant chemotherapy remains unclear...
  2. ncbi request reprint Treatment options for hepatobiliary and pancreatic cancer
    Steven R Alberts
    Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:628-37. 2007
    ..For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers...
  3. pmc Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
    George P Kim
    College of Medicine, Mayo Clinic
    Biologics 2:223-8. 2008
    ..This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment...
  4. pmc An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
    George P Kim
    Mayo Clinic Florida, Jacksonville, FL, USA
    Invest New Drugs 30:387-94. 2012
    ..This phase II study evaluated the activity and tolerability of bortezomib in unresectable hepatocellular carcinoma (HCC) patients...
  5. ncbi request reprint Oxaliplatin in the treatment of colorectal cancer
    George P Kim
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32082, USA
    Expert Opin Drug Metab Toxicol 3:281-94. 2007
    ..Future challenges with the use of oxaliplatin include defining strategies to optimize its use while avoiding treatment-limiting neurotoxicity and identification of markers predictive of response...
  6. pmc Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
    George P Kim
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:2848-54. 2009
    ..Cross-over to the other treatment on disease progression was mandated...
  7. pmc Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials
    Frank A Sinicrope
    North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:406-12. 2012
    ..Although the importance of obesity in colon cancer risk and outcome is recognized, the association of body mass index (BMI) with DNA mismatch repair (MMR) status is unknown...
  8. ncbi request reprint Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway
    George P Kim
    Division of Hematology Oncology, Mayo Clinic Jacksonville, FL, USA
    Clin Colorectal Cancer 5:S89-97. 2005
    ..This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin-containing regimens...
  9. pmc DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Natl Cancer Inst 103:863-75. 2011
    ..We determined the association of MMR status with colon cancer recurrence and examined the impact of 5-fluorouracil (FU)-based adjuvant therapy on recurrence variables...
  10. doi request reprint Retransplantation for donor-derived neuroendocrine tumor
    Rehana Begum
    Department of Transplant, Mayo Clinic, Jacksonville, FL 32224, USA
    Liver Transpl 17:83-7. 2011
    ..The high grade nature of the NET was the most important determinant of prognosis in this case. Our experience suggests that retransplantation for donor-derived NET should only be considered when tumor biology is favorable...
  11. doi request reprint Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma
    Chakri Panjala
    Divisions of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA
    Liver Transpl 18:594-601. 2012
    ..More effective chemoradiation regimens for reducing the tumor burden and the appropriate timing of LT after neoadjuvant chemoradiation require further research...
  12. doi request reprint Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)
    Michele M Corsini
    Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:3511-6. 2008
    ..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma...
  13. ncbi request reprint North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer
    George P Kim
    North Central Cancer Treatment Group, Mayo Clinic, Jacksonville, FL Mayo Clinic, Rochester, MN Sanford Clinic North Bemidgi, Bemidji, MN Cancer Center of Kansas, Wichita, KS Iowa Oncology Research Association, Des Moines, IA Metro Minnesota Community Clinical Oncology Project, St Louis Park, MN Roger Maris Cancer Center, Fargo, ND Grand Rapids Clinical Oncology Program, Grand Rapids, MI St Joseph Mercy Health System, Ann Arbor, MI
    J Clin Oncol 30:271. 2012
    ..A trial to evaluate the incorporation of Pmab into a conventional multimodality regimen and continuation as maintenance therapy was conducted in pts with LA disease...
  14. ncbi request reprint Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:572-7. 2007
    ..A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemetrexed and oxaliplatin when B(12) and folate supplementation is used...
  15. ncbi request reprint Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 56301, USA
    Cancer 104:176-82. 2005
    ..Secondary research goals were to evaluate toxicities, tolerability, and quality of life associated with this shark cartilage product...
  16. pmc Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
    Katrina S Pedersen
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Invest New Drugs 33:963-8. 2015
    ..This phase II trial was designed to determine whether 17AAG could enhance the clinical activity of gemcitabine through degradation of Chk1 in patients with stage IV pancreatic cancer...
  17. doi request reprint Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients
    JENNIFER L PETERSON
    Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL Electronic address
    Brachytherapy 12:573-9. 2013
    ..The aim of this study was to estimate the incidence of complications after (90)Y microsphere radioembolization for unresectable hepatic tumors and evaluate risk factors for late complications...
  18. pmc Obesity adversely affects survival in pancreatic cancer patients
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:5054-62. 2010
    ..The authors assessed the association of BMI with survival in a sample of pancreatic cancer patients and used epidemiologic and clinical information to understand the contribution of diabetes and hyperglycemia...
  19. pmc Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer
    Steven R Alberts
    Mayo Clinic, 1216 2nd St SW, Rochester, MN, 55902, USA
    Pharmacoeconomics 32:1231-43. 2014
    ..This study assessed the validity of those findings with real-world adjuvant chemotherapy (aCT) recommendations from the US third-party payer perspective...
  20. pmc Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial
    Steven R Alberts
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Am J Clin Oncol 35:418-23. 2012
    ..Few effective options are available for the treatment of unresectable hepatocellular carcinoma (HCC). Several phase I trials suggest promising activity of a combination of gemcitabine and docetaxel...